ABOUT CYTIVA
With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery.
We supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. Visit cytiva.com to learn more.
PRODUCT VIDEOS
FEATURED PRODUCTS
-
Explore how smart column design supports consistent, high‑yield oligonucleotide synthesis, which formats fit development, and how optimized features help improve efficiency and safety.
-
Discover a system with a flexible synthesis scale, intuitive software, and robust process control that is ideal for labs moving from research to production.
-
Research Use Only (RUO) lipid nanoparticle (LNP) reagents to deliver RNA into hematopoietic stem cells (HSCs) for cell and gene therapy applications.
-
Off-the-shelf, research use only lipid nanoparticle (LNP) reagents to deliver RNA into T-cells.
-
Bring confidence to filtration with an automated single‑use filtration system for pilot‑ and small‑scale manufacturing. This system is intended for crossflow filtration applications in both upstream and downstream workflows.
-
Learn about a scalable, single-use platform with built-in automation and regulatory compliance that enables standardized manufacturing workflows for mRNA-LNP drug product production.
-
The NanoAssemblr® commercial formulation system is an automated, single-use system for the clinical and commercial production of lipid nanoparticles (LNPs) under cGMP conditions. Designed for efficient changeover and robust manufacturing processes, the system enables operational flexibility and standardized manufacturing of genomic medicines.
-
Discover a one-stop-shop for LNP technologies that provides access to expertise in formulation and analytics for successful outcomes for payload and target applications. Explore end-to-end biopharma services and systems.
-
Designed for small-scale manufacturing, this single-use liquid chromatography system offers the performance and documentation required for a GMP-regulated environment.
-
Learn about coated magnetic particles that easily isolate and extract mRNA from a variety of sources and enable you to perform RT-PCR cDNA library construction, affinity purification, and more.
-
Synthesize oligonucleotides at scales of 10–100 mmol for early to mid-phase clinical trials or for diagnostic kits.
-
Looking for a user-friendly and compact oligonucleotide synthesizer with a large scale range? Discover a pilot-scale system that will take your drug through clinical development.
-
Explore systems for automated oligonucleotide synthesis, offered at a range of scales to support easy process development, optimization, scale up and transfer. Find the system that matches your needs.
-
The rise in approved oligo therapeutics has led to increased pressure on oligo manufacturers. Learn about modern chromatography resins, how they can help increase productivity in manufacturing, and more.
-
Discover the platform for oligonucleotide development and scale-up that is the result of 30 years of collaboration with leading oligonucleotide pharma. Explore this solution's benefits, specifications, and more.
-
OligoProcess covers a range of 10 to 1800 mmol and is suitable for quantities required in clinical phases and commercial production.
-
By combining disruptive technology platforms with unparalleled genomic medicine development expertise, we're positioned to accelerate the development of LNP formulations and drug products.
-
Explore how consistent mixing, low-volume workflows, and scale-ready design help maintain LNP quality from discovery through clinical development—reducing risk and preserving data continuity.
-
GenVoy-ILM™ T Cell Kit for mRNA, Ignite is an lipid nanoparticle (LNP) reagent mix optimized for the delivery of messenger RNA (mRNA) or Cas9 mRNA/sgRNA into activated human primary T cells.
-
With NxGen™ technology on the NanoAssemblr® Blaze™, important studies can be conducted efficiently with a process that mirrors a clinical scale implementation.
WEBINARS AND PODCASTS
APPLICATION NOTES
- mRNA Manufacturing With Fed-Batch In Vitro Transcription
- Oligonucleotide Purification And Synthesis
- TFF Cassettes With 100 kDa Membranes For RNA And LNP Applications
- Single‑Use Filtration System For Pilot‑ And Small‑Scale Manufacturing
- Exosome Isolation By TFF And Size Exclusion Chromatography
- Standardize Scale-Up And Reduce Time To Market With Mixing Cartridges
- Single-Use Liquid Chromatography System
- Coated Magnetic Particles For RNA Preparation
- Compact Oligonucleotide Synthesizer
- Oligonucleotide Synthesizers That Take You From Start To Finish
CONTACT INFORMATION
Cytiva
100 Results Way
Marlborough, MA 08855-1327
UNITED STATES
Phone: 800-526-3593
FEATURED ARTICLES
-
Non-PEG stabilizer lipids may offer a new path for LNP design. Combining strong colloidal performance with greater chemical flexibility helps address growing concerns around PEG-related immunogenicity.
-
Personalized cancer vaccines are advancing quickly, but effective delivery remains a major hurdle. Learn how mRNA and lipid nanoparticle design influence targeting, endosomal escape, and repeat dosing.
-
Gain insight into how nebulized mRNA lipid nanoparticles show preclinical success in lung delivery, offering fresh momentum for inhaled gene therapies targeting respiratory diseases.
-
Lipid nanoparticles are redefining immune cell engineering. Delve into new data that demonstrates the performance across multiple cell types and bioreactor systems, supporting their potential workflows.
-
Multiplex engineering of T cells for solid tumors requires precise delivery. Emerging LNP approaches enable co-delivery of RNA and DNA, offering a safer, more scalable path beyond viral vectors.
-
In vivo CAR-T approaches aim to reprogram T cells directly in the body using targeted lipid nanoparticles. Improved delivery to immune organs highlights new potential for scalable cell therapies.
-
Well-designed lipid nanoparticles enable safe, efficient delivery. OVA-based models show how formulation choices shape efficacy, safety, and anti-tumor outcomes in melanoma research.
-
The FDA is rethinking CMC oversight for cell and gene therapies, prioritizing science‑based justification over rigid validation models. Learn how this lifecycle‑focused approach could reduce burden.
-
Get a clear, data-driven look at the biggest pressure points in cell therapy manufacturing. Explore the trends shaping today’s production challenges and where new opportunities are emerging.
-
Cell therapy’s future hinges not just on scientific progress but on scalable manufacturing. Explore why reliability and productivity now shape viability and how modernizing operations can support growth.